Search This Blog

Friday, January 6, 2023

Fusion IND expected to be submitted in Q1 2023

 FPI-2068 IND expected to be submitted in the first quarter of 2023

FPI-1434 Phase 1 data expected in the second quarter of 2023

FPI-1966 Phase 1 study open and enrolling patients; Company expects to provide clinical data update in 2024

New actinium-225 partnership with BWXT Medical, a global leader in medical isotope supply, supports growing pipeline opportunities

https://www.biospace.com/article/releases/fusion-pharmaceuticals-reports-progress-and-provides-recent-corporate-highlights/

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)